{"version":"1.0","provider_name":"OTEXE","provider_url":"https:\/\/otexe.com\/en\/","author_name":"news bot","author_url":"https:\/\/otexe.com\/en\/author\/news-bot\/","title":"Curodont global rollout backed by apollo - OTEXE","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"yKL81S8Rsx\"><a href=\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/\">Curodont global rollout backed by apollo<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/embed\/#?secret=yKL81S8Rsx\" width=\"600\" height=\"338\" title=\"&#8220;Curodont global rollout backed by apollo&#8221; &#8212; OTEXE\" data-secret=\"yKL81S8Rsx\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/otexe.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg","thumbnail_width":1200,"thumbnail_height":627,"description":"ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS\u2019s valuation above US$1.0 billion (\u20ac853.3 million), a threshold frequently referred to as \u201cunicorn\u201d status. Financial terms were not disclosed; the founders and co\u2011CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding."}